Lurbinectedin vs. Chemotherapy in SCLC
Lurbinectedin ( Zepzelca), approved for relapsed small cell lung cancer (SCLC) after platinum chemotherapy, shows better overall survival than the standard chemo comparator topotecan in key trials.[1][2]
In the phase 3 ATLANTIS trial (n=421), lurbinectedin plus doxorubicin missed its primary endpoint, with median overall survival (OS) of 10.5 months vs. 9.3 months for topotecan plus doxorubicin (HR 0.92, p=0.43)—not statistically superior.[3] However, lurbinectedin monotherapy from the earlier phase 2b trial (n=105) beat topotecan alone: median OS 9.3 months vs. 5.3 months (HR 0.75, p=0.02), with overall response rate (ORR) 35% vs. 14%.[1][4]
Progression-Free Survival and Response Rates
Lurbinectedin monotherapy extends progression-free survival (PFS) more than topotecan: 3.5 months vs. 2.0 months (HR 0.57).[1] It also has higher ORR (35-41% vs. topotecan's 10-14%) and better disease control rates, especially in sensitive relapse (platinum-free interval >90 days).[2][5]
Topotecan, the main comparator, causes more severe cytopenias; lurbinectedin has lower rates of grade 3+ anemia (5% vs. 25%) and febrile neutropenia (5% vs. 18%).[1][3]
Who Responds Best and Real-World Data
Patients with sensitive relapse see stronger lurbinectedin benefits (OS HR 0.67 vs. topotecan).[4] Real-world studies confirm OS around 10-12 months, aligning with trials, though less selected populations show slightly shorter durations.[6]
No head-to-head data exists vs. other chemos like irinotecan or CAV (cyclophosphamide, doxorubicin, vincristine), but lurbinectedin is NCCN-preferred over topotecan for relapsed SCLC due to tolerability.[2]
When Chemo Might Still Win Out
In platinum-resistant SCLC (relapse <90 days), response rates drop to ~20% for lurbinectedin, similar to topotecan, with limited OS gains.[5] Chemo combos remain standard frontline; lurbinectedin is second-line only.
| Endpoint | Lurbinectedin Monotherapy | Topotecan |
|----------|---------------------------|-----------|
| Median OS | 9.3 months | 5.3 months |
| Median PFS | 3.5 months | 2.0 months |
| ORR | 35% | 14% |
| Grade 3+ Neutropenia | 52% | 70% |
[1]: Trigo et al., Lancet Oncol 2020
[2]: NCCN Guidelines SCLC v2.2024
[3]: ATLANTIS trial, ESMO 2023
[4]: FDA Approval Summary Zepzelca
[5]: Farago et al., J Clin Oncol 2022
[6]: Grande et al., Lung Cancer 2023